The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
New Functional Promoter Polymorphism, CETP/−629, in Cholesteryl Ester Transfer Protein (CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol Levels: Role of Sp1/Sp3 in Transcriptional Regulation
Abstract
Abstract —A new polymorphism located at position −629 (CETP/−629A/C) in the promoter of the cholesteryl ester transfer protein (CETP) gene is described. The −629A allele was associated with lower CETP mass ( P <0.0001) and higher high density lipoprotein cholesterol ( P <0.001) than the C allele in a sample of 536 control subjects from the ECTIM study. Transfection studies in HepG2 cells with a luciferase expression vector incorporating a 777-bp fragment of the CETP promoter and containing either A or C at position −629 showed significantly lower luciferase activity with the promoter fragment of the A allele (−25%, P <0.05). By gel-shift assay, DNA-protein interactions were evaluated in nuclear extracts of HepG2 cells with the use of 2 probes (A or C probe) composed of 20 bp of the promoter sequence surrounding the polymorphic site. Two specific complexes of distinct migration rate were identified with the A and the C probe. Competition with an excess of oligonucleotide containing the Sp1 consensus binding site showed that a protein(s) of the Sp transcription factor family was implicated in complex formation with the A probe but not with the C probe. Incubation with specific antibodies indicated that Sp1 and Sp3 bound specifically to the A probe. We introduced mutations in the −629-Sp1 binding site to test its functionality and to define the characteristics of transcription factor binding. We showed, by gel-shift assay, that no nuclear proteins bound to the mutated sequence. Transient transfection of HepG2 cells revealed that the expression of the mutated fragment was significantly increased compared with that of the A promoter fragment (25%, P <0.05). The mutated fragment displayed the same activity as that of the C promoter. These results indicate that Sp1 and/or Sp3 repress CETP promoter activity, whereas nuclear factors binding the C allele are without effect on promoter expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547 · cited 1×
“Four oligonucleotides were used to detect the 2 polymorphisms: (1) TGTATACCCACCCAGAG, (2) GTATACCCCCCCAGAGT, (3) TGTATACACACCCAGAG, and (4) TGTATACACCCCCAGAG (the polymorphic nucleotides are underlined and in bold).”
MethodMechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.
Mann, C. J., Yen, F. T., Grant, A. M., & Bihain, B. E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115535 · Cited by 339
Cited by
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Smith, G. D., Lawlor, D. A., Harbord, R., Timpson, N., Day, I., & Ebrahim, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040352 · Cited by 569
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 497
Boekholdt, S. M., Sacks, F. M., Jukema, J. W., Shepherd, J., Freeman, D. J., McMahon, A. D., Cambien, F., Nicaud, V., de Grooth, G. J., Talmud, P. J., et al. (2005) · Circulation · doi:10.1161/01.cir.0000153341.46271.40 · Cited by 308
Self-citationBorggreve, S. E., De Vries, R., & Dullaart, R. P. F. (2003) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2003.01263.x · Cited by 278
A review of CETP and its relation to atherosclerosis
de Grooth, G. J., Klerkx, A. H. E. M., Stroes, E. S. G., Stalenhoef, A. F. H., Kastelein, J. J. P., & Kuivenhoven, J. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400007-jlr200 · Cited by 269
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156
Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.865444 · Cited by 104
Self-citationRodríguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., & Combarros, O. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0945-2 · Cited by 47
Wu, Z., Lou, Y., Qiu, X., Liu, Y., Lu, L., Chen, Q., & Jin, W. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0118-1 · Cited by 40
“Significant associations of the TaqIB polymorphism with variations in CETP promoter activity [16] and circulating HDL-C concentrations [14] were observed, showing lower CETP concentrations and higher HDL-C levels among B2 carriers than among B1B1 homozygotes [14,17-19].”
CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk
Qureischie, H., Heun, R., Lütjohann, D., Popp, J., Jessen, F., Ledschbor-Frahnert, C., Thiele, H., Maier, W., Hentschel, F., Kelemen, P., et al. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.047 · Cited by 25
Li, Q., Huang, P., He, Q.-C., Lin, Q.-Z., Wu, J., & Yin, R.-X. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.032 · Cited by 16
Metadata
- Authors
- Dachet, C., Poirier, O., Cambien, F., Chapman, J., & Rouis, M.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2000-02
- Volume
- 20
- Issue
- 2
- Pages
- 507-515
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2084180257
- Cited by
- 168
- References
- 2
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.